RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
about
Bladder Preservation for Muscle Invasive Bladder CancerMultimodal management of muscle-invasive bladder cancerBladder Sparing Approaches for Muscle-Invasive Bladder CancersLong-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer.Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer.Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survivalLong-term urinary adverse effects of pelvic radiotherapy.Intensity modulated radiotherapy for elderly bladder cancer patients.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapySelective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder.Trimodality therapy in bladder cancer: who, what, and when?Bladder preservation protocols in the treatment of muscle-invasive bladder cancer.Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer.Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerationsRadio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control.Bladder-sparing therapy for muscle-infiltrating bladder cancer.Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.Conservative treatment of invasive bladder cancerLate pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.Bladder preservation: optimizing radiotherapy and integrated treatment strategies.Radiation therapy in urinary cancer: state of the art and perspective.Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients.Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancerThe Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder CancerTransurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome.Trimodality treatment for bladder cancer: does modern radiotherapy improve the end results?Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review.Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen.Current management of muscle-invasive bladder cancer.Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.Primary bladder preservation treatment for urothelial bladder cancer.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?Genomic characterization of response to chemoradiation in urothelial bladder cancer.Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder.Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
P2860
Q26744750-BEC39673-8610-4F71-B9D1-0BF093AC1CF5Q27011624-EACE04AB-9F11-440F-A8C7-07E8C40604D6Q28072814-99A21C4B-13F7-4AE2-AE55-FF945005E390Q30277868-468CF527-A62D-4EBD-A22F-53BB85BAD635Q33578560-20C4DA7E-33A6-4AC1-8234-E6DB3F88F4C7Q33614537-61FA9784-7E1A-44EE-90E0-3B5BC042D1D5Q34004008-ACB7781C-9589-4EF2-9102-FFBB928BE2BFQ34551018-CAD3E2E5-204A-4360-BD26-1F284D6A89B0Q34669655-E84B768B-79CE-47F4-9112-634B694DEDCFQ34786513-3243D5C9-AB72-4E05-BC50-321C9116766DQ35069296-0E383487-24BB-4276-9086-4FA085AE6EB3Q35495280-4E281116-E087-4816-BEC4-7FE232C344D9Q35647854-49CDCE2A-05B0-4A0C-9B90-677BF17807FAQ35733590-7A4C9EE5-7878-49D7-BA6B-3CF808FACA28Q35996484-5B1D3DCC-A80C-43F5-8902-A36F7AAB457AQ36854105-3455DF32-33D8-48C4-9BA4-C83C89179C9FQ36984204-AE4F1AB7-1AF2-4C59-9A4C-463CD43668A1Q37135495-27781FAB-81D7-47BD-B012-B5ED79A93132Q37193611-01F96FF4-B0F0-49D6-A0E6-0ECB7F69DEA1Q37199637-FFBE2258-5F15-4A77-97A4-46FB6234D8E1Q37292423-8C775DE7-6E5F-4094-A5F4-D15D650EEA53Q37325066-4A610FD8-5EA4-4B20-BAEA-66A45A00F430Q37335497-760A6070-07C1-49E7-9931-E72E0C8AF0F2Q37350721-5A25559C-E29F-48EE-BF31-AF1B90E4B672Q37404685-07E09E8C-D28C-4B5E-9DF1-F706CA1FA456Q37430823-C9C14D4D-C737-4745-A01D-157F501C303BQ37530349-3F3C3128-B374-44DF-ABBD-58A92F69E2FCQ37601953-9D58A410-F4DB-4E31-A60F-F665515C9F69Q37812608-6DF53A78-067C-425E-8418-98445FE7D155Q37877413-7B56A3D5-F374-4882-86FB-5D7968C155FEQ37955283-43001437-0C3E-41CD-8558-F38725D69C14Q37962658-C635B3A1-3DE5-45C1-BB65-94CF75DA168AQ37992672-8F52846A-8AE2-4C59-BCFB-8B55C1D169E5Q38118058-5DF9B4C0-425E-4D3C-A7E8-7F7D4DACAE07Q38255032-0298231E-0F6A-4273-92BA-492A424BA826Q38615547-2856D433-5897-4E42-AD8E-C754E8FBF506Q40930866-CD4C9C21-FD21-4A3B-9594-DFE94612E986Q44338887-35D9010B-2372-4A9D-B355-B97DC35DDB79Q44836523-FD8D1C18-FF7B-4E6E-A24B-D06599CEF571Q46528271-BB8CC85B-5E7A-4B1C-B0A9-EC37442E542D
P2860
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@ast
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@en
type
label
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@ast
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@en
prefLabel
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@ast
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@en
P2093
P921
P1476
RTOG 97-06: initial report of ...... MCV combination chemotherapy.
@en
P2093
Anthony L Zietman
Christopher U Jones
Donald S Kaufman
John D Roberts
Kathryn A Winter
Leonard M Toonkel
Michael P Hagan
Naill M Heney
William U Shipley
Zev Wajsman
P304
P356
10.1016/S0360-3016(03)00718-1
P407
P577
2003-11-01T00:00:00Z